Agency Forms Undergoing Paperwork Reduction Act Review, 39100-39102 [2018-16947]
Download as PDF
sradovich on DSK3GMQ082PROD with NOTICES
39100
Federal Register / Vol. 83, No. 153 / Wednesday, August 8, 2018 / Notices
comment does not include any sensitive
or confidential information. In
particular, your comment should not
include any sensitive personal
information, such as your or anyone
else’s Social Security number; date of
birth; driver’s license number or other
state identification number, or foreign
country equivalent; passport number;
financial account number; or credit or
debit card number. You are also solely
responsible for making sure that your
comment does not include any sensitive
health information, such as medical
records or other individually
identifiable health information. In
addition, your comment should not
include any ‘‘trade secret or any
commercial or financial information
which . . . is privileged or
confidential’’—as provided by Section
6(f) of the FTC Act, 15 U.S.C. 46(f), and
FTC Rule 4.10(a)(2), 16 CFR 4.10(a)(2)—
including in particular competitively
sensitive information such as costs,
sales statistics, inventories, formulas,
patterns, devices, manufacturing
processes, or customer names.
Comments containing material for
which confidential treatment is
requested must be filed in paper form,
must be clearly labeled ‘‘Confidential,’’
and must comply with FTC Rule 4.9(c).
In particular, the written request for
confidential treatment that accompanies
the comment must include the factual
and legal basis for the request, and must
identify the specific portions of the
comment to be withheld from the public
record. See FTC Rule 4.9(c). Your
comment will be kept confidential only
if the General Counsel grants your
request in accordance with the law and
the public interest. Once your comment
has been posted on the public FTC
website—as legally required by FTC
Rule 4.9(b)—we cannot redact or
remove your comment from the FTC
website, unless you submit a
confidentiality request that meets the
requirements for such treatment under
FTC Rule 4.9(c), and the General
Counsel grants that request.
The FTC Act and other laws that the
Commission administers permit the
collection of public comments to
consider and use in this proceeding as
appropriate. The Commission will
consider all timely and responsive
public comments that it receives on or
before October 9, 2018. For information
on the Commission’s privacy policy,
including routine uses permitted by the
VerDate Sep<11>2014
22:37 Aug 07, 2018
Jkt 244001
Privacy Act, see https://www.ftc.gov/
site-information/privacy-policy.
Heather Hippsley,
Acting Principal Deputy General Counsel.
[FR Doc. 2018–16936 Filed 8–7–18; 8:45 am]
BILLING CODE 6750–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[30Day–18–1072]
Agency Forms Undergoing Paperwork
Reduction Act Review
In accordance with the Paperwork
Reduction Act of 1995, the Centers for
Disease Control and Prevention (CDC)
has submitted the information
collection request titled Enhanced STD
surveillance Network (SSuN) to the
Office of Management and Budget
(OMB) for review and approval. CDC
previously published a ‘‘Proposed Data
Collection Submitted for Public
Comment and Recommendations’’
notice on March, 15, 2018 to obtain
comments from the public and affected
agencies. CDC received 37 comments
related to the previous notice. This
notice serves to allow an additional 30
days for public and affected agency
comments.
CDC will accept all comments for this
proposed information collection project.
The Office of Management and Budget
is particularly interested in comments
that:
(a) Evaluate whether the proposed
collection of information is necessary
for the proper performance of the
functions of the agency, including
whether the information will have
practical utility;
(b) Evaluate the accuracy of the
agencies estimate of the burden of the
proposed collection of information,
including the validity of the
methodology and assumptions used;
(c) Enhance the quality, utility, and
clarity of the information to be
collected;
(d) Minimize the burden of the
collection of information on those who
are to respond, including, through the
use of appropriate automated,
electronic, mechanical, or other
technological collection techniques or
other forms of information technology,
e.g., permitting electronic submission of
responses; and
(e) Assess information collection
costs.
To request additional information on
the proposed project or to obtain a copy
PO 00000
Frm 00060
Fmt 4703
Sfmt 4703
of the information collection plan and
instruments, call (404) 639–7570 or
send an email to omb@cdc.gov. Direct
written comments and/or suggestions
regarding the items contained in this
notice to the Attention: CDC Desk
Officer, Office of Management and
Budget, 725 17th Street NW,
Washington, DC 20503 or by fax to (202)
395–5806. Provide written comments
within 30 days of notice publication.
Proposed Project
Enhanced STD surveillance Network
(SSuN)—Reinstatement with Change—
Division of STD Prevention (DSTDP),
National Center for HIV/AIDS, Viral
Hepatitis, STD, and TB prevention
(NCHHSTP), Centers for Disease Control
and Prevention (CDC).
Background and Brief Description
The Enhanced STD surveillance
network project was created to provide
enhanced behavioral, demographic, and
clinical information on gonorrhea cases
reported to state and local health
departments, to provide information on
patients presenting for care in STD
clinical settings, and to provide an
infrastructure for identifying emerging
sequelae of STDs.
Enhanced SSuN continues to be a
collaboration between different
branches of the CDC Division of STD
Prevention and selected state/local
public health departments and their
associated STD specialty care clinics in
the US. Data from enhanced SSuN data
is used to (1) provide a dataset of
supplemental information on gonorrhea
case reports; (2) provide geographic
information on case reports of STDs of
interest for investigating social
determinants of STDs, (3) monitor STD
screening, incidence, prevalence,
epidemiologic and health care access
trends in populations of interest, (4)
monitor STD treatment and prevention
service practices, and (5) monitor
selected adverse health outcomes of
STDs, including neuro/ocular syphilis,
This project will continue to utilize
two distinct surveillance strategies to
collect information. The first strategy
employs facility-based sentinel
surveillance, which will abstract routine
standardized data from existing
electronic medical records for all patient
visits to participating STD clinics
during the project period. For the
facility-based component of enhanced
SSuN, participating sites have
developed common protocols
stipulating data elements to be
collected, including patient
demographics, clinical, risk and sexual
behaviors. The specified data elements
are abstracted by clinic staff from
E:\FR\FM\08AUN1.SGM
08AUN1
39101
Federal Register / Vol. 83, No. 153 / Wednesday, August 8, 2018 / Notices
existing electronic medical records for
all patient visits to participating STD
clinics. Some of the participating
facilities are satellite clinics of large
network providers where clinical data
systems are centralized. Hence, there are
10 unique clinic data managers that will
be abstracting the facility data. Each of
the clinic data managers will spend
three hours to extract and transmit data
to local/state health departments.
Individual patient records are deidentified (all patient-specific identifiers
are removed) by clinic staff before being
transmitted to health departments, who
recode the data into standardized
formats before being transmitted to CDC
through secure file transport
mechanisms. Each enhanced SSuN site
will spend 16 hours to recode and
transmit the data to CDC every other
month. At CDC, data will be aggregated
across all participating sites in a
common data structure and formatted
for analysis.
Under this revision, the second
strategy, population-based STD
surveillance is being expanded to
include not only a random sample of
reported gonorrhea cases but also
include patients diagnosed with early
syphilis that report neurologic/ocular
manifestations. For the gonorrhea
population component, a probability
sample of gonorrhea cases (up to 10%
of total gonorrhea morbidity for
participating jurisdictions) will be
contacted by health department staff for
a standardized interview either by
phone or in-person. Enhanced
gonorrhea investigations will also
include verification of treatment and an
internal health department record
review (performed on either all cases or
on the sampled cases). The focus of the
new population activity focuses on
obtaining additional clinical
information on early syphilis cases who
report neurologic/ocular symptoms. The
subset of patients reporting these
symptoms are asked to participate in an
interview to obtain additional clinical
information for a more complete
assessment of neurologic/ocular
involvement as well as obtain additional
clinical information from the diagnosing
or reporting provider. Lastly, early
syphilis cases reporting neurologic and/
or ocular symptoms are recontacted at
approximately three months following
prescribed treatment to ascertain
whether initial symptoms have
resolved.
The population data will be directly
entered into existing STD surveillance
information systems at each health
department. Data will be locally
extracted, de-identified and recoded
into standardized formats prior to being
transmitted to CDC through secure file
transport mechanisms on bimonthly
basis. Patient participation in the
interview is voluntary and refusal to
participate has no impact on other STD
services the health department provides
to persons diagnosed with gonorrhea.
This project will not collect name,
social security number, or date of birth.
A Patient ID, a unique patient identifier
assigned by the clinic or health
department depending on the
component, is requested and will be
provided to CDC for purposes of
enhanced surveillance. Patient IDs are
not linkable across enhanced SSuN
components. Sensitive information such
as sex of sex partners, HIV status, sex
work exposure, and injection drug use
are collected. All personally identifiable
information (PII) is retained by the STD
clinics and/or health departments and is
not recorded with data sent to CDC. The
electronic enhanced SSuN database is
stored on the CDC mainframe computer
and only approved Division of STD
Prevention (DSTDP) staff have access
rights to the data. As part of the
revision, we will continue to
systematically identify the risks and
potential effects of collecting,
maintaining, and disseminating PII and
to examine and evaluate alternative
processes for handling that information
to mitigate potential privacy risks and
risks to confidentiality.
Both components of enhanced SSuN
are designed to (1) Integrate traditional
surveillance methods with innovative
data management technologies to
produce high-quality, timely
surveillance and epidemiologic data, (2)
provide valuable information to direct
public health STD prevention and
control efforts, (3) enhance
understanding of the community burden
of disease, (4) identify syndemic
patterns and population at greatest risk,
and, (5) monitor long-term health
consequences of STDs. The enhanced
SSuN surveillance platform allows CDC
to establish and maintain common
standards for data collection,
transmission, and analysis, and to build
and maintain STD surveillance
expertise in 10 state/local health
departments. Such common systems,
established mechanisms of
communication, and in-place expertise
are all critical components for timely,
flexible, and high quality surveillance.
The total estimated annual burden is
3,479 hours. There are no costs to
respondents other than their time.
ESTIMATED ANNUALIZED BURDEN HOURS
Number of
respondents
Number of
responses per
respondent
Average
burden per
response
(in hours)
Form name
Data manager at Sentinel STD clinics ...........
General Public—Adults (persons diagnosed
and reported with gonorrhea or early syphilis.
Diagnosing Provider ........................................
General Public—Adults (persons with early
syphilis who were reported with neurologic/
ocular manifestations.
Data Managers: 10 local/state health department.
sradovich on DSK3GMQ082PROD with NOTICES
Type of respondents
Record Abstraction .........................................
Interview .........................................................
10
5492
6
1
3
10/60
Data for early syphilis cases ..........................
3 month follow-up telephone Interview ..........
406
203
1
1
10/60
5/60
Data cleaning/validation/reformatting .............
10
12
19
VerDate Sep<11>2014
22:37 Aug 07, 2018
Jkt 244001
PO 00000
Frm 00061
Fmt 4703
Sfmt 4703
E:\FR\FM\08AUN1.SGM
08AUN1
39102
Federal Register / Vol. 83, No. 153 / Wednesday, August 8, 2018 / Notices
Jeffrey M. Zirger,
Acting Chief, Information Collection Review
Office, Office of Scientific Integrity, Office
of the Associate Director for Science, Office
of the Director, Centers for Disease Control
and Prevention.
[FR Doc. 2018–16947 Filed 8–7–18; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2018–N–2485]
Fougera Pharmaceuticals, Inc., et al.;
Withdrawal of Approval of 27
Abbreviated New Drug Applications
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The
holders of the applications listed in the
table have informed FDA that these drug
products are no longer marketed and
have requested that FDA withdraw
approval of the applications under the
process described in § 314.150(c) (21
CFR 314.150(c)). The applicants have
also, by their requests, waived their
opportunity for a hearing. Withdrawal
of approval of an application or
abbreviated application under
§ 314.150(c) is without prejudice to
refiling.
SUPPLEMENTARY INFORMATION:
The Food and Drug
Administration (FDA or Agency) is
withdrawing approval of 27 abbreviated
new drug applications (ANDAs) from
multiple applicants. The holders of the
applications notified the Agency in
writing that the drug products were no
longer marketed and requested that the
approval of the applications be
withdrawn.
DATES: Approval is withdrawn as of
September 7, 2018.
FOR FURTHER INFORMATION CONTACT:
Trang Tran, Center for Drug Evaluation
and Research, Food and Drug
Administration, 10903 New Hampshire
Ave., Bldg. 75, Rm. 1671, Silver Spring,
MD 20993–0002, 240–402–7945,
Trang.Tran@fda.hhs.gov.
SUMMARY:
Application No.
Drug
Applicant
ANDA 061467 .........
Pyocidin-Otic (hydrocortisone and polymyxin B sulfate) Otic Solution, 5 milligrams (mg)/10,000 units per milliliter (mL).
ANDA 061653 .........
Tetrex (tetracycline phosphate complex) Capsules, Equivalent to (EQ) 100 mg
Hydrochloride (HCl), EQ 250 mg HCl and EQ 500 mg HCl.
Bristacycline (tetracycline HCl) Capsules, 250 mg and 500 mg ...........................
Penicillin V Potassium Tablets ..............................................................................
Ampicillin Capsules, 250 mg and 500 mg .............................................................
Azotrex (phenazopyridine HCl, sulfamethizole and tetracycline phosphate complex) Capsules, 50 mg/250 mg/125 mg.
Hetacillin Potassium ...............................................................................................
Bristamycin (erythromycin stearate) Tablets, EQ 250 mg base ...........................
Bristacycline (tetracycline HCl) Capsules, 250 mg and 500 mg ...........................
Tetrex (tetracycline phosphate complex) Capsules, EQ 250 mg HCl and EQ
500 mg HCl.
Azotrex (phenazopyridine HCl, sulfamethizole, and tetracycline) Capsules, 50
mg/250 mg/125 mg.
Tetrex-S (tetracycline) Syrup, 125 mg/5 mL .........................................................
Cephradine Powder for Injection ...........................................................................
Cephradine Tablets ................................................................................................
Amphotericin B for Use in Parenteral Products ....................................................
Mycolog (nystatin, neomycin sulfate, gramicidin, and triamcinolone acetonide)
Ointment.
Foamcoat (aluminum hydroxide; magnesium trisilicate) Chewable Tablets, 80
mg/20 mg (OTC).
Nuprin (ibuprofen) Tablets, 200 mg .......................................................................
Nuprin (ibuprofen) Tablets, 200 mg .......................................................................
Phrenilin with Caffeine and Codeine (acetaminophen, butalbital, caffeine, and
codeine phosphate) Capsules, 325 mg/50 mg/40 mg/30 mg.
Fougera Pharmaceuticals, Inc., 60
Baylis Rd., P.O. Box 2006, Melville,
NY 11747.
Bristol-Myers Squibb Co., P.O. Box
4000, Princeton, NJ 08543.
Do.
Do.
Do.
Do.
ANDA
ANDA
ANDA
ANDA
061658
061711
061721
061726
.........
.........
.........
.........
ANDA
ANDA
ANDA
ANDA
061790
061887
061888
061889
.........
.........
.........
.........
ANDA 061890 .........
ANDA
ANDA
ANDA
ANDA
ANDA
061891
061975
062168
062259
062543
.........
.........
.........
.........
.........
ANDA 071793 .........
ANDA 072035 .........
ANDA 072036 .........
ANDA 074911 .........
ANDA 074944 .........
Atracurium Besylate Injection, 10 mg/mL ..............................................................
ANDA 075206 .........
ANDA 077930 .........
Cytosar-U (cytarabine) for Injection USP, 100 mg/vial, 500 mg/vial, 1 gram (g)/
vial, and 2 g/vial.
Rosiglitazone Maleate and Metformin HCl Tablets, EQ 1 mg base/500 mg, EQ
2 mg base/500 mg, EQ 4 mg base/500 mg, EQ 2 mg base/1 g, and EQ 4 mg
base/1 g.
Meloxicam Tablets, 7.5 mg and 15 mg .................................................................
ANDA 080658 .........
Procaine HCl Injection, 1% and 2% ......................................................................
ANDA 083128 .........
ANDA 090181 .........
Hydrocortisone Acetate Injectable Suspension, 25 mg/mL ...................................
Ifosfamide for Injection, 1 g/20 mL and 3 g/60 mL ...............................................
sradovich on DSK3GMQ082PROD with NOTICES
ANDA 077337 .........
VerDate Sep<11>2014
22:37 Aug 07, 2018
Jkt 244001
PO 00000
Frm 00062
Fmt 4703
Sfmt 4703
E:\FR\FM\08AUN1.SGM
Do.
Do.
Do.
Do.
Do.
Do.
Do.
Do.
Do.
Do.
Guardian Drug Co., 2 Charles Court,
Dayton, NJ 08810.
Bristol-Myers Squibb Co.
Do.
Valeant Pharmaceuticals North America, LLC, 400 Somerset Corporate
Blvd., Bridgewater, NJ 08807.
Watson Laboratories, Inc., Subsidiary
of Teva Pharmaceuticals USA, Inc.,
425 Privet Rd., Horsham, PA 19044.
Teva Pharmaceuticals USA, Inc., 425
Privet Rd., Horsham, PA 19044.
Do.
Impax
Laboratories,
Inc.,
30831
Huntwood Ave., Hayward, CA 94544.
Watson Laboratories, Inc., Subsidiary
of Teva Pharmaceuticals USA, Inc.
Do.
Fresenius Kabi USA, LLC, Three Corporate Dr., Lake Zurich, IL 60047.
08AUN1
Agencies
[Federal Register Volume 83, Number 153 (Wednesday, August 8, 2018)]
[Notices]
[Pages 39100-39102]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-16947]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
[30Day-18-1072]
Agency Forms Undergoing Paperwork Reduction Act Review
In accordance with the Paperwork Reduction Act of 1995, the Centers
for Disease Control and Prevention (CDC) has submitted the information
collection request titled Enhanced STD surveillance Network (SSuN) to
the Office of Management and Budget (OMB) for review and approval. CDC
previously published a ``Proposed Data Collection Submitted for Public
Comment and Recommendations'' notice on March, 15, 2018 to obtain
comments from the public and affected agencies. CDC received 37
comments related to the previous notice. This notice serves to allow an
additional 30 days for public and affected agency comments.
CDC will accept all comments for this proposed information
collection project. The Office of Management and Budget is particularly
interested in comments that:
(a) Evaluate whether the proposed collection of information is
necessary for the proper performance of the functions of the agency,
including whether the information will have practical utility;
(b) Evaluate the accuracy of the agencies estimate of the burden of
the proposed collection of information, including the validity of the
methodology and assumptions used;
(c) Enhance the quality, utility, and clarity of the information to
be collected;
(d) Minimize the burden of the collection of information on those
who are to respond, including, through the use of appropriate
automated, electronic, mechanical, or other technological collection
techniques or other forms of information technology, e.g., permitting
electronic submission of responses; and
(e) Assess information collection costs.
To request additional information on the proposed project or to
obtain a copy of the information collection plan and instruments, call
(404) 639-7570 or send an email to [email protected]. Direct written comments
and/or suggestions regarding the items contained in this notice to the
Attention: CDC Desk Officer, Office of Management and Budget, 725 17th
Street NW, Washington, DC 20503 or by fax to (202) 395-5806. Provide
written comments within 30 days of notice publication.
Proposed Project
Enhanced STD surveillance Network (SSuN)--Reinstatement with
Change--Division of STD Prevention (DSTDP), National Center for HIV/
AIDS, Viral Hepatitis, STD, and TB prevention (NCHHSTP), Centers for
Disease Control and Prevention (CDC).
Background and Brief Description
The Enhanced STD surveillance network project was created to
provide enhanced behavioral, demographic, and clinical information on
gonorrhea cases reported to state and local health departments, to
provide information on patients presenting for care in STD clinical
settings, and to provide an infrastructure for identifying emerging
sequelae of STDs.
Enhanced SSuN continues to be a collaboration between different
branches of the CDC Division of STD Prevention and selected state/local
public health departments and their associated STD specialty care
clinics in the US. Data from enhanced SSuN data is used to (1) provide
a dataset of supplemental information on gonorrhea case reports; (2)
provide geographic information on case reports of STDs of interest for
investigating social determinants of STDs, (3) monitor STD screening,
incidence, prevalence, epidemiologic and health care access trends in
populations of interest, (4) monitor STD treatment and prevention
service practices, and (5) monitor selected adverse health outcomes of
STDs, including neuro/ocular syphilis,
This project will continue to utilize two distinct surveillance
strategies to collect information. The first strategy employs facility-
based sentinel surveillance, which will abstract routine standardized
data from existing electronic medical records for all patient visits to
participating STD clinics during the project period. For the facility-
based component of enhanced SSuN, participating sites have developed
common protocols stipulating data elements to be collected, including
patient demographics, clinical, risk and sexual behaviors. The
specified data elements are abstracted by clinic staff from
[[Page 39101]]
existing electronic medical records for all patient visits to
participating STD clinics. Some of the participating facilities are
satellite clinics of large network providers where clinical data
systems are centralized. Hence, there are 10 unique clinic data
managers that will be abstracting the facility data. Each of the clinic
data managers will spend three hours to extract and transmit data to
local/state health departments. Individual patient records are de-
identified (all patient-specific identifiers are removed) by clinic
staff before being transmitted to health departments, who recode the
data into standardized formats before being transmitted to CDC through
secure file transport mechanisms. Each enhanced SSuN site will spend 16
hours to recode and transmit the data to CDC every other month. At CDC,
data will be aggregated across all participating sites in a common data
structure and formatted for analysis.
Under this revision, the second strategy, population-based STD
surveillance is being expanded to include not only a random sample of
reported gonorrhea cases but also include patients diagnosed with early
syphilis that report neurologic/ocular manifestations. For the
gonorrhea population component, a probability sample of gonorrhea cases
(up to 10% of total gonorrhea morbidity for participating
jurisdictions) will be contacted by health department staff for a
standardized interview either by phone or in-person. Enhanced gonorrhea
investigations will also include verification of treatment and an
internal health department record review (performed on either all cases
or on the sampled cases). The focus of the new population activity
focuses on obtaining additional clinical information on early syphilis
cases who report neurologic/ocular symptoms. The subset of patients
reporting these symptoms are asked to participate in an interview to
obtain additional clinical information for a more complete assessment
of neurologic/ocular involvement as well as obtain additional clinical
information from the diagnosing or reporting provider. Lastly, early
syphilis cases reporting neurologic and/or ocular symptoms are
recontacted at approximately three months following prescribed
treatment to ascertain whether initial symptoms have resolved.
The population data will be directly entered into existing STD
surveillance information systems at each health department. Data will
be locally extracted, de-identified and recoded into standardized
formats prior to being transmitted to CDC through secure file transport
mechanisms on bimonthly basis. Patient participation in the interview
is voluntary and refusal to participate has no impact on other STD
services the health department provides to persons diagnosed with
gonorrhea.
This project will not collect name, social security number, or date
of birth. A Patient ID, a unique patient identifier assigned by the
clinic or health department depending on the component, is requested
and will be provided to CDC for purposes of enhanced surveillance.
Patient IDs are not linkable across enhanced SSuN components. Sensitive
information such as sex of sex partners, HIV status, sex work exposure,
and injection drug use are collected. All personally identifiable
information (PII) is retained by the STD clinics and/or health
departments and is not recorded with data sent to CDC. The electronic
enhanced SSuN database is stored on the CDC mainframe computer and only
approved Division of STD Prevention (DSTDP) staff have access rights to
the data. As part of the revision, we will continue to systematically
identify the risks and potential effects of collecting, maintaining,
and disseminating PII and to examine and evaluate alternative processes
for handling that information to mitigate potential privacy risks and
risks to confidentiality.
Both components of enhanced SSuN are designed to (1) Integrate
traditional surveillance methods with innovative data management
technologies to produce high-quality, timely surveillance and
epidemiologic data, (2) provide valuable information to direct public
health STD prevention and control efforts, (3) enhance understanding of
the community burden of disease, (4) identify syndemic patterns and
population at greatest risk, and, (5) monitor long-term health
consequences of STDs. The enhanced SSuN surveillance platform allows
CDC to establish and maintain common standards for data collection,
transmission, and analysis, and to build and maintain STD surveillance
expertise in 10 state/local health departments. Such common systems,
established mechanisms of communication, and in-place expertise are all
critical components for timely, flexible, and high quality
surveillance. The total estimated annual burden is 3,479 hours. There
are no costs to respondents other than their time.
Estimated Annualized Burden Hours
----------------------------------------------------------------------------------------------------------------
Number of Average burden
Type of respondents Form name Number of responses per per response
respondents respondent (in hours)
----------------------------------------------------------------------------------------------------------------
Data manager at Sentinel STD clinics.. Record Abstraction...... 10 6 3
General Public--Adults (persons Interview............... 5492 1 10/60
diagnosed and reported with gonorrhea
or early syphilis.
Diagnosing Provider................... Data for early syphilis 406 1 10/60
cases.
General Public--Adults (persons with 3 month follow-up 203 1 5/60
early syphilis who were reported with telephone Interview.
neurologic/ocular manifestations.
Data Managers: 10 local/state health Data cleaning/validation/ 10 12 19
department. reformatting.
----------------------------------------------------------------------------------------------------------------
[[Page 39102]]
Jeffrey M. Zirger,
Acting Chief, Information Collection Review Office, Office of
Scientific Integrity, Office of the Associate Director for Science,
Office of the Director, Centers for Disease Control and Prevention.
[FR Doc. 2018-16947 Filed 8-7-18; 8:45 am]
BILLING CODE 4163-18-P